Arvinas Inc is primarily active in the biotechnology industry.

Some of the main competitors of Arvinas Inc. in the market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, and Pfizer Inc.

Arvinas Inc, founded in 2013, is a biopharmaceutical company based in New Haven, Connecticut. The company focuses on developing targeted protein degradation therapies to treat various diseases such as cancer and genetically driven conditions. Arvinas utilizes its proprietary PROTAC® (PROteolysis TArgeting Chimeras) platform, allowing selective protein degradation and removal from cells. This innovative approach offers the potential for more effective and precise treatments. Arvinas has partnered with pharmaceutical companies and has a diverse pipeline targeting different diseases. With its cutting-edge technology and strategic partnerships, Arvinas aims to revolutionize the field of protein degradation therapy for the benefit of patients worldwide.

Arvinas Inc, a leading biotechnology company, has achieved several significant milestones. The company successfully developed and secured approval for its lead product candidate, ARV-110, which targets the androgen receptor protein for the treatment of metastatic castration-resistant prostate cancer. Arvinas has also advanced its second program, ARV-471, for the treatment of breast cancer, into clinical trials. Furthermore, the company has entered into strategic collaborations with leading pharmaceutical companies to expand the application of its PROTAC® technology platform. Arvinas' dedication to innovative drug development and strategic partnerships showcases its commitment to revolutionizing the field of targeted protein degradation.

Arvinas Inc is primarily present in the United States.

Arvinas Inc represents values of innovation, integrity, and commitment to advancing healthcare through targeted protein degradation. The company's corporate philosophy focuses on developing novel therapeutics using their proprietary PROTAC® platform. Arvinas Inc strives to discover and deliver transformative medicines that address significant unmet medical needs. By harnessing the power of protein degradation, Arvinas Inc aims to revolutionize the treatment of diseases such as cancer and other serious conditions. Through their cutting-edge research and dedication to improving patients' lives, Arvinas Inc continues to be a leader in the field of targeted protein degradation.

Analysts currently set an average price target of 13.50 USD for the Arvinas stock (median: 14.28 USD), implying +50.5 % versus the latest price. The consensus is based on 26 analyst ratings.

Arvinas Analyst Price Targets 2026

26 analysts currently rate the Arvinas stock: 16 recommend buying, 9 holding and 1 selling. For 2026, analysts expect Arvinas to generate revenue of 297.57 M USD and earnings per share of -0.16 USD.

Arvinas Analyst Price Targets 2026

Converted at the current exchange rate, the Arvinas share trades at 7.75 EUR (8.97 USD).

The Arvinas share (ARVN) is listed on 1 stock exchanges, including: NASDAQ (ARVN).

Arvinas Inc is a biotechnology company based in New Haven, Connecticut, USA. They specialize in the development of therapeutics based on protein degradation. Their goal is to treat diseases that traditional approaches, such as enzyme inhibition or receptor blockade, are not sufficient for. The basic principle of protein degradation is to specifically break down faulty or diseased proteins by targeting them. Arvinas focuses on the development of PROTACs (Proteolysis-Targeting Chimeras), which consist of two binding molecules. One molecule binds to the faulty protein, while the other molecule marks it for degradation by the body's own proteasome. Arvinas' core areas include oncology, neurodegeneration, inflammatory diseases, and rare genetic disorders. By manipulating proteins, they potentially can develop individualized treatment approaches for each disease. In oncology, Arvinas is focused on developing therapeutics for breast cancer, prostate cancer, and lung cancer. In neurodegeneration, their aim is to effectively combat Alzheimer's, Parkinson's, or ALS. In inflammation research, their focus is on rheumatoid arthritis and fibrosis. Arvinas has recently entered into partnerships with leading pharmaceutical companies. They are working with Pfizer on the development of immuno-oncology therapeutics. Another partnership exists with Genentech, a sister company of Roche, for the discovery and development of therapeutics in the field of neurodegeneration. However, Arvinas is not only involved in drug development but also offers research services for PROTAC development. They explore new target molecules and develop specific PROTACs for pharmaceutical industry clients. This is an important growth market for the company as more companies recognize the advantages of protein degradation as a therapeutic approach. Another significant growth field for Arvinas is the use of "traps." These are synthetic molecules that mark and intercept faulty proteins before they reach their target location. Arvinas has developed their own technologies for this and has already achieved initial successes, particularly in cancer treatment. Overall, Arvinas Inc is a promising biotechnology company with a broad pipeline of therapeutics based on protein degradation. With strong partnerships with various companies and an open research infrastructure, they will be able to continue their research and development of therapeutics for a variety of diseases.

The expected revenue of Arvinas is 297.57 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Arvinas is -10.53 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Arvinas is currently -55.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Arvinas stock.

The price-to-sales ratio (P/S) of Arvinas is currently 1.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Arvinas stock.

The Eulerpool Quality Score for Arvinas is 3/10.

The ISIN of Arvinas is US04335A1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Arvinas is A2N6VP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Arvinas is ARVN. The ticker symbol is used to trade Arvinas shares on the stock exchange.

Arvinas paid dividends every year for the past 0 years.

Arvinas is assigned to the 'Health' sector.

The dividends of Arvinas are distributed in USD.